ReNeuron encouraged by progress in stroke and RP treatments

ReNeuron Group PLC is a leading, clinical-stage stem cell business.

The company’s primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

() announced that the first UK subject has been treated at the Oxford Eye Hospital, part of Oxford University Hospitals NHS Foundation Trust, as part of the second stage of clinical trials.

The pharma company is evaluating its candidate for the treatment of retinitis pigmentosa (RP), an inherited, degenerative eye disease.

The remaining study participants are expected to be treated by the end of 2021, the AIM-listed firm said.

ReNeuron’s hRPC therapeutic candidate is undergoing Phase 2a clinical evaluations for the treatment of RP, which affects 1 in 4,000 people in the US and worldwide. The expanded study encompasses four sites worldwide, with two sites in the US as well as the recently activated sites in the UK and in Spain.

ReNeuron Group PLC (AIM:RENE) has published what it describes as “extremely compelling” data that provides “clear pre-clinical proof-of-concept” that its exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by neurological diseases.

Work carried out by the University of Salamanca, Spain, assessed whether the stem cell-derived technology could carry its payload to the corpus striatum – a region of the brain affected by stroke, Parkinson’s Disease and Huntington’s Disease.

ReNeuron Group PLC (AIM:RENE, FRA:RQE1) said it had restarted in all geographies recruitment to its phase IIa human retinal progenitor (hRPC) cell therapy trial treating patients with degenerative eye disease retinitis pigmentosa.

Live Company Group PLC (AIM:LVCG) will bring a taste of the Antarctic throughout the centre of Hampshire town Eastleigh next month, as part of a new contract for its BRICKLIVE ‘March of the Penguins’ display.

The 38% rise in the share price of ReNeuron Group PLC (AIM:RENE) probably hasn’t come as a huge surprise to those that follow the stem cell specialist.

There was quite a lot to unpack from Monday’s announcement – one in which it said its exosome technology had delivered therapeutic proteins to a hard to access region of the human brain.

ReNeuron Group’s Olav Hellebo joins Proactive to talk about their exosome technology which has shown it can deliver therapeutic proteins to a hard to access region of the human brain.

Exosomes are powerful mediators that carry all the signalling and the machinery necessary to change the behaviour of a cell.

As Hellobo explains, the line created by ReNeuron comes from its CTX technology and has been developed to carry the therapeutic proteins as well as delivering it to an exact destination – an area of the brain called the corpus striatum.